One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2020-134314
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2020 |
 Citations: 5 |
Affiliation: The University of Texas MD Anderson Cancer Center, University of Pennsylvania, UPMC Hillman Cancer Center, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center, Columbia University Irving Medical Center, Mary Crowley Cancer Research Center, Sir Charles Gairdner Hospital, Linear Clinical Research, University of California, San Francisco, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Swedish Medical Center, Loxo Oncology at Lilly (United States), University of Miami, Sylvester Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Emory University, Sarah Cannon, Tennessee Oncology, The Maria Sklodowska-Curie National Research Institute of Oncology, The Ohio State University, Churchill Hospital, Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique de Nantes, Nantes Université, Inserm, Derriford Hospital, University Hospitals Plymouth NHS TrustLOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström’s Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
